Fragment-Based Discovery of Irreversible Covalent Inhibitors of Cysteine Proteases Using Chlorofluoroacetamide Library.
activity-based protein profiling
chlorofluoroacetamide
covalent inhibitor
cysteine protease
fragment-based drug discovery
Journal
Chemical & pharmaceutical bulletin
ISSN: 1347-5223
Titre abrégé: Chem Pharm Bull (Tokyo)
Pays: Japan
ID NLM: 0377775
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
6
5
2021
Statut:
ppublish
Résumé
Fragment-based approach combined with electrophilic reactive compounds is a powerful strategy to discover novel covalent ligands for protein target. However, the promiscuous reactivity often interferes with identification of the fragments possessing specific binding affinity to the targeted protein. In our study, we report the fragment-based covalent drug discovery using the chemically tuned weak reactivity of chlorofluoroacetamide (CFA). We constructed a small fragment library composed of 30 CFA-appended compounds and applied it to the covalent ligand screening for cysteine protease papain as a model protein target. Using the fluorescence enzymatic assay, we identified CFA-benzothiazole 30 as a papain inhibitor, which was found to irreversibly inactivate papain upon enzyme kinetic analysis. The formation of the covalent papain-30 adduct was confirmed using electrospray ionization mass spectrometry analysis. The activity-based protein profiling (ABPP) experiment using an alkynylated analog of 30 (i.e., 30-yne) revealed that 30-yne covalently labeled papain with high selectivity. These data demonstrate potential utility of the CFA-fragment library for de novo discovery of target selective covalent inhibitors.
Identifiants
pubmed: 33132374
doi: 10.1248/cpb.c20-00547
doi:
Substances chimiques
Acetamides
0
Cysteine Proteinase Inhibitors
0
Fluorescent Dyes
0
Ligands
0
acetamide
8XOE1JSO29
Cysteine Proteases
EC 3.4.-
Papain
EC 3.4.22.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM